Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TAOK3 | Q9H2K8 | 4/20 | 0.50 |
| ▸ | TAOK1 | Q7L7X3 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16371380 | 1.00 | KMT2A (0.55) | KMT2AALDH1A1MEN1HTTL3MBTL1 | |
| SCHEMBL18351572 | 0.89 | KMT2A (0.57) | KMT2AALDH1A1MEN1HTTL3MBTL1 | |
| SCHEMBL29131632 | 0.87 | OPRK1 (0.59) | KMT2AALDH1A1MEN1HTTOPRK1 | |
| SCHEMBL29131630 | 0.87 | OPRK1 (0.59) | KMT2AALDH1A1MEN1HTTOPRK1 | |
| SCHEMBL5651521 | 0.85 | TAOK3 (0.58) | KMT2AALDH1A1MEN1HTTOPRK1 | |
| SCHEMBL18337978 | 0.84 | XIAP (0.52) | KMT2AALDH1A1MEN1HTTL3MBTL1 | |
| SCHEMBL18799786 | 0.84 | XIAP (0.52) | KMT2AALDH1A1MEN1HTTL3MBTL1 | |
| SCHEMBL16392446 | 0.84 | XIAP (0.52) | KMT2AALDH1A1MEN1HTTL3MBTL1 | |
| SCHEMBL16392356 | 0.82 | KMT2A (0.64) | KMT2AALDH1A1MEN1HTTOPRK1 | |
| SCHEMBL18351571 | 0.82 | KMT2A (0.64) | KMT2AALDH1A1MEN1HTTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637518-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160376307-A1 | IAP ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3019517-A1 | IAP ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006524-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376307-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | KMT2A 4302/4885ALDH1A1 4013/4885MEN1 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.